当事務所は、ライフサイエンス及び医療分野において豊富な実務経験を有しており、クライアントのビジネスニーズ及び法的ニーズの両方を満たすことができる法的サービスを提供しています。ライフサイエンス及び医療分野に特化した専門性の高い弁護士チームによる、法的コンプライアンスを重視した、シンプルかつ実行可能なプランや最善のアドバイスを提供することで、クライアントからの厚い信頼を得ています。
同チームは、中国のライフサイエンス及び医療事業に関する法律知識に富んでおり、その複雑なビジネス環境について造詣が深い弁護士を多数擁しています。また、同分野に関連する業界団体とも密接な連携関係があり、それらの組織・委員会のメンバーとして、関連業界の準則（行動規範）の制定に参加した実績もあります。
同弁護士チームは、医薬品の研究開発、臨床試験、製薬、ライフサイエンス、動物用医薬品、バイオ医薬品、医療機器、卸売・小売、医療機関及びその他の医療サービス業者、並びに当該分野への投資等、ライフサイエンス及び医療産業に関する全面的な法的サービスをクライアントに提供することができます。また、同弁護士チームは、本分野に関わるコンプライアンス法務においては業界トップの地位を占めています。
同チームは、公立病院の体制改革、非公立医療機関の形態変更などの複雑な案件の処理に長けており、クライアントの実情に合う、カスタマイズされた解決案を提案し、クライアントのビジネス目標の達成をサポートしています。
本分野における主に取扱い業務は以下のとおりです。
- コンプライアンスに関する提案及びレビュー
- 取引に関するプランニング及び交渉サポート
- 製品ライン及び市場エリアの拡大
- プロジェクトファイナンス、M&A、事業再編
- 知的財産の保護
- 許諾契約及び販売代理店契約
- 臨床試験及び有害事象の紛争解決等
代表的な取扱い事例
- Represented NFC to acquire United Family Healthcare, Deals of the Year - 2019 China Business Law Journal
- Represented Novartis to acquire GlaxoSmithKline in the field of tumor, which is one of the largest M&A deals in global Life science and healthcare industry in 2015
- Represented Zhejiang Tianyuan Bio Pharmaceutical Co., Ltd to sell its controlling shares to Novartis in Switzerland, which is the first foreign capital to enter the field of human vaccine through the acquisition of controlling shares
- Represented China Resources Pharmaceutical Group and Beijing Municipal Government to reorganise Beijing BeiYao group, involving assets of about 50 billion yuan, four listed companies, which is the largest M & A transaction in China life science and healthcare industry
- Represented BeiGenes (NASDAQ listed company) and Amgen (NASDAQ listed company) to complete a major transaction in the field of biomedicine
- Represented BeiGene (NASDAQ listed company) and Celgene (NASDAQ listed company) to accomplish a strategic transaction globally relative to oncologic sector of Celgene
- Represented Siemens Group to complete the initial listing offering (IPO) of its medical business sector - Siemens Healthcare AG in Frankfurt Stock Exchange (the largest IPO in the European market in 2018)
外部機構・団体からの評価
“The team are familiar with the life science industry and provide solution-oriented and practical advice.”
" lauds a client, who further says:“They have good insights and understanding. They give practical solutions.”
——Chambers-Greater China Region 2024
Benefiting from Universal's knowledge of the market, one client praised, "The team provides good compliance support with deep insight into the healthcare industry and an in-depth understanding of the market."
——Chambers-Greater China Region 2023
受賞歴
Awards
- 2024, Nominated in Healthcare Law Firm of the Year, Asian Legal Business
- 2024, China Law Awards: Healthcare & Life Sciences Law Firm of the Year; LEGALBAND
- 2024, China Capital Markets Awards – Healthcare Law Firm of the Year, DAWKINS
- 2023, The Legal 500 China Awards 2023: Life Sciences & Healthcare Firm of the Year, The Legal 500
- 2023, Nominated in China Law Awards - Healthcare & Life Sciences Law Firm of the Year, LEGALBAND
- 2015-2016, 2018-2022, Healthcare & Life Sciences Law Firm of the Year for several times, LEGALBAND
- 2018-2020, 2022-2023, Five years of China Law Awards: Healthcare Law Firm of the Year, Asian Legal Business
- 2013-2016,2018,2020, Six years of Healthcare & Life Sciences PRC Law Firm of the Year, China Law & Practice
- 2016, 2018-2021, China Business Law Awards: Healthcare, China Business Law Journal
- 2019, Deals of the Year: NFC acquires United Family Healthcare, China Business Law Journal
- 2023, Best Business Development Service, eighteenth China Pharmaceutical and Medtech Business Development Forum (“CHBD Forum”)
- 2022, Best Business Development Service, the seventeenth China Pharmaceutical and Medtech Business Development Forum (“CHBD Forum”)
- 2021, Best Business Development Service, the sixteenth China Pharmaceutical and Medtech Business Development Forum (“CHBD Forum”)
- 2020, Best Business Development Service, the fifteenth China Pharmaceutical and Medtech Business Development Forum (“CHBD Forum”)
- 2012, Healthcare Law Firm of the Year, Acquisition International
- 2021, Healthcare & Life Sciences Law Firm of the Year, the fifth Healthcare Investment ExcellentList
- 2020, Pharmaceuticals, Medical and Biotech Legal Adviser of the Year, Mergermarket China M&A Awards 2020, Mergermarket
- 2020, Pharmaceuticals, Medical and Biotech M&A Deal of the Year - BeiGene, Ltd. (Amgen, Inc.), Mergermarket China M&A Awards 2020, Mergermarket
Rankings
- 2022-2024, Band 1 Law Firm in Healthcare, Chambers and Partners Greater China Region
- 2013-2021, Band 1 firm in Healthcare, Chambers and Partners Asia Pacific
- 2018-2024, Top-tier firm in Healthcare and Life Sciences, The Legal 500 Asia Pacific
- 2016-2024, Top-tier firm in Healthcare & Life Sciences, LEGALBAND
- 2022, Top-tier firm in Healthcare & Life Sciences, DAWKINS
- 2023-2024, Outstanding firm in Pharmaceuticals and life sciences, asialaw
- 2022-2023, Highly Recommended firm in Pharmaceuticals and life sciences, asialaw
- 2019-2021, Recommended firm in Pharmaceuticals and life sciences, asialaw
- ニュース
-
- GLO advises CARsgen Therapeutics Holdings Limited (HKEX: 02171) on its initial p...
- GLO helps the Restructure of China Operation of Siemens Healthineers for its suc...
- GLO Represents BeiGene in a Mega Deal in China Biopharma
- GLO advises Vincent Medical Holdings Limited on its IPO and listing on the main ...
- GLO Sponsores Sino-Europe BioPartnering 2014
